Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Quality Assessment of Pre-Clinical Studies of Chimeric Antigen Receptor T-Cell Therapy Products: A Point of Focus on Safety

Author(s): Vikas Maharshi, Diksha Diksha and Pooja Gupta*

Volume 17, Issue 2, 2022

Published on: 14 January, 2022

Page: [129 - 135] Pages: 7

DOI: 10.2174/1574886316666210728101333

Price: $65

Abstract

Background: Serious adverse reactions have been reported with the use of Chimeric Antigen Receptor (CAR) T-cell therapy in a clinical setting despite the success of these products in pre- clinical stages of development.

Objective: We evaluated the quality of available pre-clinical safety data of CAR T-cell therapy products.

Methods: A 21 items safety checklist was designed specifically for CAR T-cell. Literature was searched using search/MeSH terms in PubMed (October 2019 – February 2020). Studies were screened from title and abstract. Original pre-clinical researches related to CAR T-cell anti-cancer therapy were included.

Results: Of the search results, 152 studies (3 in vivo, 39 in vitro, and 110 combined) were included. Only 7.9% of studies were specifically designed to evaluate/ improve product safety. Eleven studies included target antigen(s), and no study included co-stimulatory molecule(s) expressed exclusively by the tumor tissue and/or CAR T-cells. One study used CRISPR-Cas9 for CAR gene insertion. The use of switch-off mechanism and purity assessment of CAR T-cell products were reported in 13.2% and 8.6% studies, respectively. Of the 113 studies with in vivo components, immuno- competent animal models were used in 24.8%. Measurements of blood pressure, temperature, body weight, and serum cytokines were reported in 0, 2.7, 29.2, and 27.4% studies, respectively. The tissue distribution and CAR T-cells persistence were reported in 26.5% of studies. The surface expression level of CAR, functional characterization of the product, and use of control were reported in >90% of studies.

Conclusion: The majority of the checklist parameters were not reported in the pre-clinical publications to be adequately predictive of the safety of CAR T-cells in a clinical setting.

Keywords: Adverse effects, anticancer, CAR T-cell, chimeric antigen receptor, quality of preclinical studies, safety

« Previous Next »
Graphical Abstract

[1]
PDQ Cancer Information Summaries [Internet Bethesda (MD): National Cancer Institute (US). Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)-Health Professional Version. Available from: https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq [Accessed on August 07, 2020
[2]
Dana-Farber/Boston Children’s cancer and Blood Disorders Center. Relapsed Acute Lymphoblastic Leukemia. Available from: http://www.danafarberbostonchildrens.org/conditions/leukemia-and-lymphoma/relapsed-acute-lymphoblastic-leukemia.aspx [Accessed on August 07, 2020
[3]
FDA Advisory Committee Briefing Document. Tisagenlecleucel (CTL019) for the treatment of pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. 2017. Available from: https://www.fda.gov/media/106093/download[Accessed on August 07, 2020
[4]
Wegner A. Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities. Immunotherapy 2017; 9(8): 669-80.
[http://dx.doi.org/10.2217/imt-2017-0028] [PMID: 28653571]
[5]
Guidance Document EHA. EHA guidance document the process of car-t cell therapy in europe. HemaSphere 2019; 3(4): e280.
[http://dx.doi.org/10.1097/HS9.0000000000000280] [PMID: 31723850]
[6]
National Cancer Institute. CAR T-cell therapy approved by FDA for mantle cell lymphoma. 2020. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-brexucabtagene-mantle-cell-lymphoma [Accessed on October 07, 2020
[7]
Halim L, Ajina A, Maher J. Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety. Best Pract Res Clin Haematol 2018; 31(2): 117-25.
[http://dx.doi.org/10.1016/j.beha.2018.04.002] [PMID: 29909912]
[8]
Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T-cell therapy. Mol Ther Methods Clin Dev 2016; 4: 92-101.
[http://dx.doi.org/10.1016/j.omtm.2016.12.006] [PMID: 28344995]
[9]
Li Y, Huo Y, Yu L, Wang J. Quality control and nonclinical research on CAR T-cell products: general principles and key issues. Engineering 2019; 5: 122-31.
[http://dx.doi.org/10.1016/j.eng.2018.12.003]
[10]
Price G, Baird KUS. Scientific and regulatory considerations for gene modified T cell therapy. Available from: https://pharm.ucsf.edu/sites/pharm.ucsf.edu/files/cersi/media-browser/Graeme%20Price%20and%20Kristin%20Baird.pdf [Accessed on August 07, 2020
[11]
Kalaitsidou m, Kueberuwa G, Schutt A, Gilham DE. car t-cell therapy: Toxicity and the relevance of preclinical models. Immunotherapy 2015; 7: 487-97.
[http://dx.doi.org/10.2217/imt.14.123]
[12]
Morgan RA, Boyerinas B. Genetic modification of T cells. Biomedicines 2016; 4(2): 1-14.
[http://dx.doi.org/10.3390/biomedicines4020009] [PMID: 28536376]
[13]
Liu J, Zhou G, Zhang L, Zhao Q. Building potent chimeric antigen receptor T cells with CRISPR genome editing. Front Immunol 2019; 10: 456.
[http://dx.doi.org/10.3389/fimmu.2019.00456] [PMID: 30941126]
[14]
Harris D. CAR-T safety and efficacy endpoints: A checklist for preclinical development. Genet Eng Biotechnol News 2018; 38: 3.
[http://dx.doi.org/10.1089/gen.38.03.07]
[15]
Cazaux M, Grandjean CL, Lemaître F, et al. Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity. J Exp Med 2019; 216(5): 1038-49.
[http://dx.doi.org/10.1084/jem.20182375] [PMID: 30936262]
[16]
Guedan S, Calderon H, Posey AD Jr, Maus MV. Engineering and design of chimeric antigen receptors. Mol Ther Methods Clin Dev 2018; 12: 145-56.
[http://dx.doi.org/10.1016/j.omtm.2018.12.009] [PMID: 30666307]
[17]
Hashem Boroojerdi M, Rahbarizadeh F, Safarzadeh Kozani P, Kamali E, Safarzadeh Kozani P. Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia. Med Oncol 2020; 37(11): 100.
[http://dx.doi.org/10.1007/s12032-020-01416-3] [PMID: 33047234]
[18]
Brandt LJB, Barnkob MB, Michaels YS, Heiselberg J, Barington T. Emerging approaches for regulation and control of CAR T cells: A mini review. Front Immunol 2020; 11: 326.
[http://dx.doi.org/10.3389/fimmu.2020.00326] [PMID: 32194561]
[19]
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer 2018; 6(1): 56.
[http://dx.doi.org/10.1186/s40425-018-0343-9] [PMID: 29907163]
[20]
Panjwani MK, Smith JB, Schutsky K, et al. Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor t cells in dogs with spontaneous b cell lymphoma. Mol Ther 2016; 24(9): 1602-14.
[http://dx.doi.org/10.1038/mt.2016.146] [PMID: 27401141]
[21]
European Medicines Agency. Choice of control group in clinical trials. 2001. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-10-choice-control-group-clinical- trials-step-5_en.pdf [Accessed October 07, 2020.

Rights & Permissions Print Cite
Article Metrics
25
1
© 2024 Bentham Science Publishers | Privacy Policy